Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | CD274 positive |
Therapy | Cetrelimab |
Indication/Tumor Type | melanoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | melanoma | predicted - sensitive | Cetrelimab | Phase Ib/II | Actionable | In a Phase I/II trial, Cetrelimab (JNJ-63723283) treatment demonstrated safety, and resulted in an overall response rate (ORR) of 18.6% (38/204), clinical benefit rate (CBR) of 31.3% (64/204), median progression-free survival (mPFS) of 2.8 mo, and median overall survival (mOS) of 17.8 mo in advanced solid tumor patients, with an ORR of 50% (4/8, 1 complete and 3 partial responses), and CBR of 75% (6/8) in CD274 (PD-L1)-positive melanoma patients (PMID: 35298698; NCT02908906). | 35298698 |
PubMed Id | Reference Title | Details |
---|---|---|
(35298698) | First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. | Full reference... |